Helixgate

Helixgate

Uncategorized

STAT+: 3 burning questions senators had for the NIH director

Published

on

Thursday’s Senate Appropriations Committee hearing was intended to focus on President Trump’s proposed budget for the National Institutes of Health’s fiscal year 2027 budget. 

Instead, many of the senator’s questions for NIH Director Jay Bhattacharya and the five institute directors who joined him focused on more immediate concerns: a leadership vacuum at the agency’s sprawling infectious disease institute amid two outbreaks, the slow pace of funding over the course of the current fiscal year, and the impact of various Trump administration policies on the research community. 

Here are three questions that were raised during the hearing: 

Continue to STAT+ to read the full story…

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Published

on

After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.​ ​Read More

Continue Reading

Uncategorized

Chile offers new data on food warning label efficacy

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Continue Reading

Uncategorized

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

Published

on

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

Continue Reading
Advertisement

Trending